JAZZ.O Hits 52-Week High on Positive Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18 Nov 25
Source: SeekingAlpha
Shares of Jazz Pharmaceuticals (JAZZ.O) surged by 20.49% today, reaching a new 52-week high of $170.11. This significant price movement follows the announcement of positive results from the Phase 3 HERIZON-GEA-01 trial, which demonstrated that Ziihera, in combination with chemotherapy, significantly improved progression-free survival and overall survival for patients with HER2-positive gastroesophageal adenocarcinoma. The stock's breakout above previous resistance levels signals strong bullish momentum, reflecting investor confidence in the drug's potential as a new standard of care. Looking ahead, Jazz plans to submit a supplemental Biologics License Application to the FDA in 2026, further bolstering its market position.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188.00 USD and a high forecast of 263.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
Current: 163.980
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
